We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > About Us > Paul Hardman

Paul Hardman

Head of Scientific Affairs at Broughton

As head of scientific affairs at Broughton, Paul manages a team of consultants specializing in understanding product chemistry across pharmaceuticals and consumer products. Paul studied a BSc in Pharmacology from the University of Sheffield and commenced his career at Vectura, where experience was gained in developing dry powder inhaled medicines. He was the co-inventor of a novel powder dispersion engine design for a passive dry powder inhaler, with potential for use across a range of API and with a range of inhalers. Following ten years at Vectura, Paul led the quality control laboratory at one of Perrigo’s manufacturing sites. Prior to joining Broughton, Paul led product characterization at Nerudia and Imperial Brands. This included assessment of next generation nicotine products spanning e-vapour, oral, and heated tobacco areas at all stages in the products' lifecycle. In this role, Paul has met with the FDA to discuss e-vapour product chemistry approaches to meet premarket tobacco product application requirements and written regulatory packages to support the marketing of products in the UK, US, Japan, New Zealand, and the Middle East.

Latest content from Paul Hardman

The Degradation Pathways of Cannabinoids and How to Manage Them – Part 2

In the second of two articles, scientists from Broughton, a regulatory consultancy currently focused on EU and UK cannabis regulation, discuss the susceptibility of cannabinoids to degrade and summarize the main degradation pathways of THC and CBD.

VIEW

The Degradation Pathways of Cannabinoids and How to Manage Them – Part 1

In the first of two articles, scientists from Broughton, a regulatory consultancy currently focused on EU and UK cannabis regulation, discuss the susceptibility of cannabinoids to degrade and summarize the main degradation pathways of THC and CBD.

VIEW